Skip to main content
. 2020 Jul 24;108(3):616–624. doi: 10.1002/cpt.1964

Figure 2.

Figure 2

Pharmacodynamic changes in patients administered i.v. emactuzumab q2w according to dose and exposure. (a) Change from baseline in CD68+ CD163+ macrophage levels in paired tumor biopsy samples with exposure. (b) Change from baseline in CD163+ and colony‐stimulating factor‐1 receptor‐positive skin macrophages with exposure. [Colour figure can be viewed at wileyonlinelibrary.com]